Literature DB >> 11097340

Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.

D W Nebert1.   

Abstract

Individual risk of toxicity or cancer reflects the amount of exposure to environmental agents, combined with one's underlying genetic predisposition. More than six dozen human ecogenetic polymorphisms have been described; whereas some of these have been demonstrated to be associated with altered risks of toxicity or cancer, others presently remain equivocal and require further study. Thus, genetic differences in the regulation, expression and activity of "environmental susceptibility genes" can be decisive in defining susceptibility to toxicity or cancer. "Drug-metabolizing enzymes" (DMEs) are regarded as one class of environmental susceptibility genes. DME genes have actually existed on this planet for more than 2.5 billion years, and might more appropriately be named "effector-metabolizing enzymes." Receptors controlling DME levels have been called "DME receptors." DMEs have functioned in many critical life processes in prokaryotes and, more recently, in countless basic functions in plants and animals - events that evolved long before the existence of pharmaceutical companies and apothecaries. DME genes exist in every eukaryotic cell and probably in all prokaryotes. Virtually all environmental agents act as either agonists or antagonists - in competing with endogenous ligands that bind to DME receptors and/or competing as substrates for the DMEs. Over the past decade it has become clear that each of us has our own "individual fingerprint" of unique alleles coding for DMEs. The underlying genetic predisposition of each patient will reflect combinations of poor- and extensive-metabolizer phenotypes; if these enzymes cooperate in the same metabolic pathway for any given drug or environmental agent, such ecogenetic variability might be synergistic and lead to as much as 30- or >40-fold differences in activation or degradation. The end result can be large interindividual differences in risk of environmentally caused toxicity or cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097340     DOI: 10.1515/CCLM.2000.124

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

1.  Metabolism of [D10]phenanthrene to tetraols in smokers for potential lung cancer susceptibility assessment: comparison of oral and inhalation routes of administration.

Authors:  Yan Zhong; Jing Wang; Steven G Carmella; J Bradley Hochalter; Diane Rauch; Andrew Oliver; Joni Jensen; Dorothy K Hatsukami; Pramod Upadhyaya; Cheryl Zimmerman; Stephen S Hecht
Journal:  J Pharmacol Exp Ther       Date:  2011-04-22       Impact factor: 4.030

2.  Quantitation of N-acetyl-S-(9,10-dihydro-9-hydroxy-10-phenanthryl)-L-cysteine in human urine: comparison with glutathione-S-transferase genotypes in smokers.

Authors:  Pramod Upadhyaya; Priyanka Rao; J Bradley Hochalter; Zhong-Ze Li; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

Review 3.  [Genetics, pain and analgesia].

Authors:  U Stamer; B Bayerer; F Stüber
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

4.  Analysis of r-7,t-8,9,c-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene in human urine: a biomarker for directly assessing carcinogenic polycyclic aromatic hydrocarbon exposure plus metabolic activation.

Authors:  Yan Zhong; Steven G Carmella; J Bradley Hochalter; Silvia Balbo; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-11-04       Impact factor: 3.739

5.  Analysis of phenanthrene and benzo[a]pyrene tetraol enantiomers in human urine: relevance to the bay region diol epoxide hypothesis of benzo[a]pyrene carcinogenesis and to biomarker studies.

Authors:  Stephen S Hecht; Steven G Carmella; Peter W Villalta; J Bradley Hochalter
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

6.  Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development.

Authors:  Natalie C Sadler; Premchendar Nandhikonda; Bobbie-Jo Webb-Robertson; Charles Ansong; Lindsey N Anderson; Jordan N Smith; Richard A Corley; Aaron T Wright
Journal:  Drug Metab Dispos       Date:  2016-04-15       Impact factor: 3.922

7.  Quantitation of a minor enantiomer of phenanthrene tetraol in human urine: correlations with levels of overall phenanthrene tetraol, benzo[a]pyrene tetraol, and 1-hydroxypyrene.

Authors:  J Bradley Hochalter; Yan Zhong; Shaomei Han; Steven G Carmella; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2011-01-13       Impact factor: 3.739

8.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

Authors:  Elena A Gaikovitch; Ingolf Cascorbi; Przemyslaw M Mrozikiewicz; Jürgen Brockmöller; Roland Frötschl; Karla Köpke; Thomas Gerloff; Jury N Chernov; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2003-07-15       Impact factor: 2.953

Review 9.  Timing is everything: consequences of transient and sustained AhR activity.

Authors:  Kristen A Mitchell; Cornelis J Elferink
Journal:  Biochem Pharmacol       Date:  2008-11-06       Impact factor: 5.858

10.  Genetic variation and pharmacogenomics: concepts, facts, and challenges.

Authors:  Margret R Hoehe; Thomas Kroslak
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.